Format

Send to

Choose Destination
Proc Natl Acad Sci U S A. 2016 Sep 20;113(38):10625-30. doi: 10.1073/pnas.1611751113. Epub 2016 Sep 6.

Rabex-5 is a lenalidomide target molecule that negatively regulates TLR-induced type 1 IFN production.

Author information

1
Laboratory of Immune Regulation, World Premier Immunology Frontier Research Centre, Osaka University, Osaka 565-0871, Japan.
2
Laboratory of Immune Regulation, World Premier Immunology Frontier Research Centre, Osaka University, Osaka 565-0871, Japan kishimoto@ifrec.osaka-u.ac.jp.

Abstract

Immunomodulatory drugs (IMiDs) are a family of compounds derived from thalidomide. Binding of the IMiD molecule to the Lon protease Cereblon initiates the degradation of substrates via the ubiquitin proteasome pathway. Here, we show that Cereblon forms a complex with Rabex-5, a regulator of immune homeostasis. Treatment with lenalidomide prevented the association of Cereblon with Rabex-5. Conversely, mutation of the IMiD binding site increased Cereblon-Rabex-5 coimmunoprecipitation. The thalidomide binding region of Cereblon therefore regulates the formation of this complex. Knockdown of Rabex-5 in the THP-1 macrophage cell line up-regulated Toll-like receptor (TLR)-induced cytokine and type 1 IFN production via a STAT1/IRF activating pathway. Thus, we identify Rabex-5 as a IMiD target molecule that functions to restrain TLR activated auto-immune promoting pathways. We propose that release of Rabex-5 from complex with Cereblon enables the suppression of immune responses, contributing to the antiinflammatory properties of IMiDs.

KEYWORDS:

Cereblon; IMiD; STAT1; TLR; interferon

PMID:
27601648
PMCID:
PMC5035883
DOI:
10.1073/pnas.1611751113
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center